SIDNEY KIMMEL CANCER CENTER AT JEFFERSON Cancer Risk Assessment and Clinical Cancer Genetics Program The mission of the Cancer Risk Assessment and Clinical Cancer Genetics Program, which launched in late 2014, is to offer comprehensive expert genetic counseling, advanced genetic testing, and novel research opportunities to all patients concerned about cancer risk for themselves and their families. We evaluate patients with all types of cancer concerns, with thorough assessment of risk factors, family cancer history, and personal medical history for patients to make an informed decision about genetic testing. Every patient case is reviewed at our weekly Genetics Case Conference which includes genetic counselors, advanced practice nurse in genetics, medical oncologists, and licensed social worker. Since late 2014, we have discussed over 1,000 patients in our Genetics Case Conference for genetic testing, cancer screening, and management. Our recommendations span tailored cancer screening and cancer risk reduction, lifestyle modification, implications for family members, and psychosocial support for patients and their families. The “Innovation Arm” of our program centers around going “Beyond Standard of Care” by developing novel research studies to address needs in cancer risk, genetic counseling, genetic testing, and accelerate the knowledge of cancer predisposition and patient fulfillment with genetic testing. Of absolute importance toward achieving this goal is to embrace and promote translational research involving participants of our program to gain critical insights into genes involved with cancer predisposition, cancer risk factors, and behavioral factors that motivate decision-making for testing. An example of going “Beyond Standard of Care” is our novel Genitourinary (GU) Genetics Clinic – the first in the country to offer genetic counseling and genetic testing for prostate cancer patients linked with multidisciplinary evaluation of prostate cancer. Through the GU genetics clinic, we have developed the first prospective multigene testing study for prostate cancer and thus are addressing a need for comprehensive genetic evaluation for men with this potentially heritable cancer and their families. The Innovation Arm also includes unique patient-centered initiatives, such as a developing peer-support program (“Genetics Buddy”) for patients to talk to other individuals who have undergone cancer risk assessment or genetic testing when making their own decisions. We also address community and underserved population needs regarding cancer awareness and education through research and community-based programs. Indeed, our impact spans to the Sidney Kimmel Cancer Network hospitals in Philadelphia and surrounding suburbs, southern NJ, northeastern PA, and the Pocono region where we provide genetic counseling and cancer risk assessment in-person or via telegenetics. I invite you to review this Newsletter to learn more about our stellar staff and providers, our current research activities, and ways to support our mission. Sincerely, Veda N. Giri, MD Director Cancer Risk Assessment and Clinical Cancer Genetics Program Until every cancer is cured • Genetic Evaluation of Men (GEM) Registry – A registry of men with and at risk for prostate cancer. We collect medical, family history, behavioral data as well as DNA for cancer risk research. We are exploring the role of genes, diet, environment, and lifestyle factors in cancer development in patients and their families to develop the field of genetic testing for prostate cancer. GEM Clinical Multigene Testing Study– Offers a clinically available multigene test to men with and at risk for prostate cancer. The goal is to uncover genetic mutations for inherited prostate cancer to support genetic testing guidelines for men and their families for this highly heritable cancer. The results inform cancer risk and management for patients and their families. • Cancer Genetics Risk Registry – A registry of patients with any cancer or at-risk individuals evaluated for genetic risk. We will collect medical, family history, behavioral data as well as DNA for cancer risk research. We are exploring the role of genes, diet, environment, and lifestyle factors in cancer development in patients and their families. • Genetics Buddy Program– This initiative is building upon an existing peer-support program for patients to focus in the genetics arena. We are pulling together a cadre of patients with and without cancer who have undergone genetic testing or cancer risk assessment to provide peer support to patients and their families. • ICARE Study (Inherited Cancer Risk Evaluation) – This study is exploring genetic counseling and testing in the new era of tumor sequencing potentially informing inherited cancer risk. The goal is to characterize the inherited mutation spectrum, correlation to personal and family history, and assess genetic providers and patients regarding their knowledge, comfort level, and satisfaction with the genetic counseling and testing process based around tumor sequencing results. • Telegenetics – In an effort to expand access to our cutting-edge cancer genetics program, we have launched our Telegenetics initiative. This tele-health approach provides patients the option to have genetic counseling remotely via a secure, web-based application in order to maximize access to our program. Patients will also have opportunities to engage in research through the telehealth initiative. • Cancer Disparities – Cancer risk assessment knowledge, attitudes, and uptake projects are being developed and instituted for minority populations who experience high rates of cancer, such as African American, Latino, and Asian Indians (where the incidence of cancer is rising). Novel approaches are being studied including developing educational materials, employing technology, and enrolling individuals onto research studies to get much needed insights regarding the genetic contribution to cancer risk in diverse populations. Innovation Arm Initiatives Sidney Kimmel Cancer Network and Cancer Genetics We are currently providing cancer genetic services for the following Jefferson Health and Sidney Kimmel Cancer Network Members: • Aria – Jefferson Health • Mercy Health System (Mercy Fitzgerald and Nazareth) • Delta Medix, PC, Scranton, PA • Kennedy University Hospital, Sewell, NJ • Doylestown Hospital, Doylestown, PA Philanthropy Philanthropic funds are a vital way to keep the innovative research and patient-centered initiatives moving forward. If you are interested to learn more about our program or to make a donation, please contact Laura Gross at 215-503-5285. Veda N. Giri, MD Program Director Veda N. Giri, MD is an Associate Professor in Medical Oncology and Cancer Biology at the Sidney Kimmel Cancer Center (SKCC) at Jefferson. She is a medical oncologist with a clinical and research interest in inherited cancer risk assessment. She is the Director of Cancer Risk Assessment and Clinical Cancer Genetics which provides patients with genetic counseling, genetic testing, and cancer screening recommendations along with the opportunity to take part in innovative research and patient-centered initiatives. Dr. Giri received her medical degree from Sidney Kimmel Medical College (previously Jefferson Medical College), and proceeded to complete her residency in Internal Medicine and fellowship in Hematology-Oncology at the University of Michigan. She then completed advanced training in molecular cancer genetics and cancer risk assessment at Fox Chase Cancer Center (FCCC). From 2006-2014, she directed prostate cancer risk assessment at FCCC, developing studies focused on evaluating the role of genetic markers in prostate cancer risk assessment. In 2014, Dr. Giri assumed her role as Director of Cancer Risk Assessment and Clinical Cancer Genetics at SKCC with the overall goal to develop a comprehensive translational program for patient evaluation and research endeavors. Dr. Giri has served on national committees including the National Comprehensive Cancer Network Prostate Cancer Early Detection Panel and NIH PDQ ® Cancer Genetics Editorial Board, contributing expertise in prostate cancer risk assessment and prostate cancer genetics at the national level. She is continuing research efforts to identify and characterize the inherited basis of prostate cancer to develop the field of genetic testing for prostate cancer. A further goal of Dr. Giri’s research is to study cancer risk in diverse populations, and address community needs regarding engagement in cancer risk assessment. SPRING 2017 Message from the Program Director For more information about our Cancer Risk Assessment and Clinical Cancer Genetics Program or to refer a patient, please contact Karen Robison at 215-955-1011 or karen.robison@jefferson.edu
2
Embed
SIDNEY KIMMEL CANCER CENTER AT JEFFERSON Cancer Risk Assessment and Clinical Cancer ...hospitals.jefferson.edu/content/dam/health/PDFs/... · 2019-05-07 · National Comprehensive
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
S I D N E Y K I M M E L C A N C E R C E N T E R A T J E F F E R S O N
Cancer Risk Assessment and Clinical Cancer Genetics Program
The mission of the Cancer Risk Assessment and Clinical Cancer Genetics Program, which launched in late 2014, is to
offer comprehensive expert genetic counseling, advanced genetic testing, and novel research opportunities to all patients
concerned about cancer risk for themselves and their families. We evaluate patients with all types of cancer concerns, with
thorough assessment of risk factors, family cancer history, and personal medical history for patients to make an informed
decision about genetic testing. Every patient case is reviewed at our weekly Genetics Case Conference which includes
genetic counselors, advanced practice nurse in genetics, medical oncologists, and licensed social worker. Since late 2014,
we have discussed over 1,000 patients in our Genetics Case Conference for genetic testing, cancer screening, and
management. Our recommendations span tailored cancer screening and cancer risk reduction, lifestyle modification,
implications for family members, and psychosocial support for patients and their families.
The “Innovation Arm” of our program centers around going “Beyond Standard of Care” by developing novel research
studies to address needs in cancer risk, genetic counseling, genetic testing, and accelerate the knowledge of cancer
predisposition and patient fulfillment with genetic testing. Of absolute importance toward achieving this goal is to embrace
and promote translational research involving participants of our program to gain critical insights into genes involved with
cancer predisposition, cancer risk factors, and behavioral factors that motivate decision-making for testing. An example of
going “Beyond Standard of Care” is our novel Genitourinary (GU) Genetics Clinic – the first in the country to offer genetic
counseling and genetic testing for prostate cancer patients linked with multidisciplinary evaluation of prostate cancer.
Through the GU genetics clinic, we have developed the first prospective multigene testing study for prostate cancer and
thus are addressing a need for comprehensive genetic evaluation for men with this potentially heritable cancer and their
families. The Innovation Arm also includes unique patient-centered initiatives, such as a developing peer-support program
(“Genetics Buddy”) for patients to talk to other individuals who have undergone cancer risk assessment or genetic testing
when making their own decisions. We also address community and underserved population needs regarding cancer
awareness and education through research and community-based programs. Indeed, our impact spans to the Sidney
Kimmel Cancer Network hospitals in Philadelphia and surrounding suburbs, southern NJ, northeastern PA, and the
Pocono region where we provide genetic counseling and cancer risk assessment in-person or via telegenetics.
I invite you to review this Newsletter to learn more about our stellar staff and providers, our current research
activities, and ways to support our mission.
Sincerely,
Veda N. Giri, MD
Director Cancer Risk Assessment and Clinical Cancer Genetics Program
Unti l eve r y c ance r i s cure d
• Genetic Evaluation of Men (GEM) Registry – A registry
of men with and at risk for prostate cancer. We collect
medical, family history, behavioral data as well as DNA
for cancer risk research. We are exploring the role of
genes, diet, environment, and lifestyle factors in cancer
development in patients and their families to develop the
field of genetic testing for prostate cancer. GEM Clinical
Multigene Testing Study– Offers a clinically available
multigene test to men with and at risk for prostate
cancer. The goal is to uncover genetic mutations for
inherited prostate cancer to support genetic testing
guidelines for men and their families for this highly
heritable cancer. The results inform cancer risk and
management for patients and their families.
• Cancer Genetics Risk Registry – A registry of patients
with any cancer or at-risk individuals evaluated for
genetic risk. We will collect medical, family history,
behavioral data as well as DNA for cancer risk research.
We are exploring the role of genes, diet, environment,
and lifestyle factors in cancer development in patients
and their families.
• Genetics Buddy Program – This initiative is building upon
an existing peer-support program for patients to focus
in the genetics arena. We are pulling together a cadre of
patients with and without cancer who have undergone
genetic testing or cancer risk assessment to provide peer
support to patients and their families.
• ICARE Study (Inherited Cancer Risk Evaluation) – This
study is exploring genetic counseling and testing in
the new era of tumor sequencing potentially informing
inherited cancer risk. The goal is to characterize the
inherited mutation spectrum, correlation to personal and
family history, and assess genetic providers and patients
regarding their knowledge, comfort level, and satisfaction
with the genetic counseling and testing process based
around tumor sequencing results.
• Telegenetics – In an effort to expand access to our
cutting-edge cancer genetics program, we have launched
our Telegenetics initiative. This tele-health approach
provides patients the option to have genetic counseling
remotely via a secure, web-based application in order
to maximize access to our program. Patients will also
have opportunities to engage in research through
the telehealth initiative.
• Cancer Disparities – Cancer risk assessment knowledge,
attitudes, and uptake projects are being developed and
instituted for minority populations who experience high
rates of cancer, such as African American, Latino, and
Asian Indians (where the incidence of cancer is rising).
Novel approaches are being studied including developing
educational materials, employing technology, and
enrolling individuals onto research studies to get much
needed insights regarding the genetic contribution to
cancer risk in diverse populations.
Innovation Arm Initiatives
Sidney Kimmel Cancer Network and Cancer Genetics
We are currently providing cancer genetic services for
the following Jefferson Health and Sidney Kimmel Cancer
Network Members:
• Aria – Jefferson Health
• Mercy Health System (Mercy Fitzgerald and Nazareth)
• Delta Medix, PC, Scranton, PA
• Kennedy University Hospital, Sewell, NJ
• Doylestown Hospital, Doylestown, PA
Philanthropy
Philanthropic funds are a vital way to keep the
innovative research and patient-centered initiatives
moving forward. If you are interested to learn more
about our program or to make a donation, please
contact Laura Gross at 215-503-5285.
Veda N. Giri, MDProgram Director
Veda N. Giri, MD is an Associate Professor in Medical Oncology and Cancer Biology at the Sidney Kimmel Cancer Center (SKCC) at Jefferson. She is a medical oncologist with a clinical and research interest in inherited cancer risk assessment. She is the Director of Cancer Risk Assessment and Clinical Cancer Genetics which provides patients with genetic counseling, genetic testing, and cancer screening recommendations along with the opportunity to take part in innovative research and patient-centered initiatives.
Dr. Giri received her medical degree from Sidney Kimmel Medical College (previously Jefferson Medical College), and proceeded to complete her residency in Internal Medicine and fellowship in Hematology-Oncology at the University of Michigan. She then completed advanced training in molecular cancer genetics and cancer risk assessment at Fox Chase Cancer Center (FCCC). From 2006-2014, she directed prostate cancer risk assessment at FCCC, developing studies focused on evaluating the role of genetic markers in prostate cancer risk assessment. In 2014, Dr. Giri assumed her role as Director of Cancer Risk Assessment and Clinical Cancer Genetics at SKCC with the overall goal to develop a comprehensive translational program for patient evaluation and research endeavors. Dr. Giri has served on national committees including the National Comprehensive Cancer Network Prostate Cancer Early Detection Panel and NIH PDQ® Cancer Genetics Editorial Board, contributing expertise in prostate cancer risk assessment and prostate cancer genetics at the national level. She is continuing research efforts to identify and characterize the inherited basis of prostate cancer to develop the field of genetic testing for prostate cancer. A further goal of Dr. Giri’s research is to study cancer risk in diverse populations, and address community needs regarding engagement in cancer risk assessment.
SPRING 2017
Message from the Program Director
For more information about our Cancer Risk
Assessment and Clinical Cancer Genetics Program
or to refer a patient, please contact Karen Robison at